PMC:7386875 / 54268-54450
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T397 | 173-181 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T17 | 61-73 | Chemical | denotes | dipyridamole | http://purl.obolibrary.org/obo/CHEBI_4653 |
| T31968 | 78-88 | Chemical | denotes | nafamostat | http://purl.obolibrary.org/obo/CHEBI_135466 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T184 | 0-182 | Sentence | denotes | Several other therapies with antiplatelet effects, including dipyridamole and nafamostat, are currently being evaluated for their potential role in reducing the severity of COVID-19. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1786 | 61-73 | Chemical | denotes | dipyridamole | MESH:D004176 |
| 1787 | 78-88 | Chemical | denotes | nafamostat | MESH:C032855 |
| 1801 | 173-181 | Disease | denotes | COVID-19 | MESH:C000657245 |